The University of Tokyo has signed a deal to develop a personalised cancer vaccine. A team led by Professor Masaru Iwata from the university's Graduate School for Advanced Studies in Life Sciences and Technology (GLAST) have developed an antibody that can recognise cancerous cells as they grow inside Matching the results will allow them to identify neoantigens that would be expected to have the ability to provoke an immune response.
The University of Tokyo has signed a deal to develop a personalised cancer vaccine. Researchers, in collaboration with the Kanagawa Cancer Centre and BrightPath Biotherapeutics, will seek to identify gene mutations unique to cancer cells and then use mass spectrometry analysis to identify peptides on the cancer cells after isolating them. Matching the results will allow them to identify neoantigens that would be expected to have the ability to provoke an immune response.